Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.
pharmaphorum20h
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
The request follows a similar move by Eli Lilly, which has asked for a ban on other parties making copies of its tirzepatide-based therapies Mounjaro for diabetes and Zepbound for obesity ...